Cargando…

Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study

INTRODUCTION: When and how to intensify treatment in patients with type 2 diabetes (T2D) not achieving glycated hemoglobin (HbA1c) targets with oral antidiabetic drugs (OADs) in clinical practice remains a matter of clinical preference. This pilot study was conducted using the retrospective observat...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Xuejun Victor, Ayyagari, Rajeev, Lubwama, Robert, Shi, Lizheng, Price-Haywood, Eboni G., Hollander, Priscilla, Fonseca, Vivian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136385/
https://www.ncbi.nlm.nih.gov/pubmed/32112204
http://dx.doi.org/10.1007/s13300-020-00783-4
_version_ 1783518236823781376
author Peng, Xuejun Victor
Ayyagari, Rajeev
Lubwama, Robert
Shi, Lizheng
Price-Haywood, Eboni G.
Hollander, Priscilla
Fonseca, Vivian
author_facet Peng, Xuejun Victor
Ayyagari, Rajeev
Lubwama, Robert
Shi, Lizheng
Price-Haywood, Eboni G.
Hollander, Priscilla
Fonseca, Vivian
author_sort Peng, Xuejun Victor
collection PubMed
description INTRODUCTION: When and how to intensify treatment in patients with type 2 diabetes (T2D) not achieving glycated hemoglobin (HbA1c) targets with oral antidiabetic drugs (OADs) in clinical practice remains a matter of clinical preference. This pilot study was conducted using the retrospective observational data from such patients to evaluate the impact on HbA1c of three treatment sequences: simultaneous initiation of basal insulin (BI) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA; Cohort 1); BI followed by GLP-1 RA initiation within a 90-day timeframe (Cohort 2); or BI followed by GLP-1 RA initiation beyond 90 days (Cohort 3). METHODS: Data from the regional US electronic medical records database, Research Action for Health Network (REACHnet), were extracted for all patients with T2D aged ≥ 18 years who had encounter dates between January 2011 and August 2017 and ≥ 1 HbA1c laboratory value(s) < 90 days before BI initiation and ≥ 2 HbA1c laboratory values within 1 year after BI initiation and who met the inclusion criteria for GLP-1 RA initiation set for Cohorts 1, 2, or 3. The primary endpoints were the proportion of patients achieving HbA1c < 7.0%, which was estimated via Kaplan–Meier analysis, and change in HbA1c within 12 months. RESULTS: Overall, 869 patients were analyzed, of whom 109 were in Cohort 1, 301 in Cohort 2, and 459 in Cohort 3. Baseline HbA1c was 10.3 ± 2.1, 10.3 ± 2.0, and 10.2 ± 2.1% for these three cohorts, respectively. Statistically significantly more patients in Cohort 1 than in Cohort 3 achieved HbA1c < 7.0% (33.4 vs. 20.9%, respectively; p  = 0.0186). Mean observed reductions in HbA1c at 12 months were − 1.7% (Cohort 1), − 1.5% (Cohort 2), and − 1.3% (Cohort 3). CONCLUSIONS: Simultaneous initiation of BI and GLP-1 RA achieves glycemic control more effectively than sequential initiation of BI with GLP-1 RA added beyond 90 days.
format Online
Article
Text
id pubmed-7136385
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-71363852020-04-09 Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study Peng, Xuejun Victor Ayyagari, Rajeev Lubwama, Robert Shi, Lizheng Price-Haywood, Eboni G. Hollander, Priscilla Fonseca, Vivian Diabetes Ther Brief Report INTRODUCTION: When and how to intensify treatment in patients with type 2 diabetes (T2D) not achieving glycated hemoglobin (HbA1c) targets with oral antidiabetic drugs (OADs) in clinical practice remains a matter of clinical preference. This pilot study was conducted using the retrospective observational data from such patients to evaluate the impact on HbA1c of three treatment sequences: simultaneous initiation of basal insulin (BI) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA; Cohort 1); BI followed by GLP-1 RA initiation within a 90-day timeframe (Cohort 2); or BI followed by GLP-1 RA initiation beyond 90 days (Cohort 3). METHODS: Data from the regional US electronic medical records database, Research Action for Health Network (REACHnet), were extracted for all patients with T2D aged ≥ 18 years who had encounter dates between January 2011 and August 2017 and ≥ 1 HbA1c laboratory value(s) < 90 days before BI initiation and ≥ 2 HbA1c laboratory values within 1 year after BI initiation and who met the inclusion criteria for GLP-1 RA initiation set for Cohorts 1, 2, or 3. The primary endpoints were the proportion of patients achieving HbA1c < 7.0%, which was estimated via Kaplan–Meier analysis, and change in HbA1c within 12 months. RESULTS: Overall, 869 patients were analyzed, of whom 109 were in Cohort 1, 301 in Cohort 2, and 459 in Cohort 3. Baseline HbA1c was 10.3 ± 2.1, 10.3 ± 2.0, and 10.2 ± 2.1% for these three cohorts, respectively. Statistically significantly more patients in Cohort 1 than in Cohort 3 achieved HbA1c < 7.0% (33.4 vs. 20.9%, respectively; p  = 0.0186). Mean observed reductions in HbA1c at 12 months were − 1.7% (Cohort 1), − 1.5% (Cohort 2), and − 1.3% (Cohort 3). CONCLUSIONS: Simultaneous initiation of BI and GLP-1 RA achieves glycemic control more effectively than sequential initiation of BI with GLP-1 RA added beyond 90 days. Springer Healthcare 2020-02-28 2020-04 /pmc/articles/PMC7136385/ /pubmed/32112204 http://dx.doi.org/10.1007/s13300-020-00783-4 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Brief Report
Peng, Xuejun Victor
Ayyagari, Rajeev
Lubwama, Robert
Shi, Lizheng
Price-Haywood, Eboni G.
Hollander, Priscilla
Fonseca, Vivian
Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study
title Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study
title_full Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study
title_fullStr Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study
title_full_unstemmed Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study
title_short Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study
title_sort impact of simultaneous versus sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists on hba1c in type 2 diabetes: a retrospective observational study
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136385/
https://www.ncbi.nlm.nih.gov/pubmed/32112204
http://dx.doi.org/10.1007/s13300-020-00783-4
work_keys_str_mv AT pengxuejunvictor impactofsimultaneousversussequentialinitiationofbasalinsulinandglucagonlikepeptide1receptoragonistsonhba1cintype2diabetesaretrospectiveobservationalstudy
AT ayyagarirajeev impactofsimultaneousversussequentialinitiationofbasalinsulinandglucagonlikepeptide1receptoragonistsonhba1cintype2diabetesaretrospectiveobservationalstudy
AT lubwamarobert impactofsimultaneousversussequentialinitiationofbasalinsulinandglucagonlikepeptide1receptoragonistsonhba1cintype2diabetesaretrospectiveobservationalstudy
AT shilizheng impactofsimultaneousversussequentialinitiationofbasalinsulinandglucagonlikepeptide1receptoragonistsonhba1cintype2diabetesaretrospectiveobservationalstudy
AT pricehaywoodebonig impactofsimultaneousversussequentialinitiationofbasalinsulinandglucagonlikepeptide1receptoragonistsonhba1cintype2diabetesaretrospectiveobservationalstudy
AT hollanderpriscilla impactofsimultaneousversussequentialinitiationofbasalinsulinandglucagonlikepeptide1receptoragonistsonhba1cintype2diabetesaretrospectiveobservationalstudy
AT fonsecavivian impactofsimultaneousversussequentialinitiationofbasalinsulinandglucagonlikepeptide1receptoragonistsonhba1cintype2diabetesaretrospectiveobservationalstudy